Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

The Importance of Patient Input into Development of Outcomes in Idiopathic Inflammatory Myopathy

ADAM M. HUBER
The Journal of Rheumatology January 2019, 46 (1) 5-6; DOI: https://doi.org/10.3899/jrheum.181045
ADAM M. HUBER
IWK Health Centre, Halifax, Nova Scotia, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: adam.huber@iwk.nshealth.ca

In this issue of The Journal, Mecoli, et al report the results of an international survey of healthcare providers and patients with idiopathic inflammatory myopathy (IIM) to examine and compare perceptions of disease features and effects1. This work is part of an overall program to develop patient-reported outcomes in IIM, given that it is recognized that these have not been well studied to date2. This study raises a number of important issues and has implications for future research.

This work follows the procedures described by the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) initiative. OMERACT is the acronym for an international, informally organized network initiated in 1992, which aimed at improving outcome measurement in rheumatology3. Using this methodology confers a number of important strengths to this work. It contributes to transparency by explicitly describing the process by which decisions are made throughout the process. It requires that decision making be data-driven, reducing the risk of the biases of the investigators compromising the results. The methods also mandate a broad input, by requiring the inclusion of patient research partners in the working group and involvement of researchers from at least 3 continents4. In this way, the likelihood of the results being valid and generalizable is increased. In the end, endorsement by OMERACT requires that the results pass the OMERACT filter: that is, do the resulting measures meet the criteria of truth, discrimination, and feasibility?3.

The field of rheumatology has shown considerable leadership in the area of patient-reported outcomes, a topic that has been reviewed5. The work of Mecoli, et al extends this to include patients with IIM1. The same group have previously reported the results of qualitative research to explore the adequacy of current outcome measures in IIM and were able to demonstrate that outcomes of importance to patients with IIM were not assessed by current measures6. These additional outcomes included pain, fatigue, and impairment in cognitive function. The importance of these outcomes to patients with IIM has been confirmed by the findings of the current work in this issue of The Journal1. In addition, the work emphasizes the critical importance of engaging patients in the development of outcome measures. It should also be noted that despite the terminology patient-reported, the simple act of reporting an outcome does not mean that it is either important or relevant to patients. It remains necessary to ascertain which outcomes matter to the patients being studied.

Not surprisingly, priorities of patients may differ from those of their healthcare providers, because of the perspective granted by the lived experience of illness. The outcomes that are rated highly by care providers may be those that have been traditionally assessed, those that currently have validated assessment tools, or those perceived to be modifiable. There may be significant overlap, such as in this study, in which both patients and care providers rated muscle symptoms as the most important outcome1. However, patients were more likely to highly rate fatigue, cognitive effects, and difficulty sleeping, while care providers were more likely to highly rate joint symptoms, lung symptoms, and dysphagia. These differences need to be used to identify important foci for future research.

Tory, et al have recently conducted an unrelated study that compared rankings of quality measures by patients with juvenile dermatomyositis and their families, and care providers7. Both groups agreed on the 5 most important quality measures: overall quality of life, timely diagnosis, access to rheumatology care, normalization of function/strength, and ability for self-care. However, there were also important differences. Patients and their parents rated overall quality of life as the most important quality measure, while it was ranked only fifth by the care providers. There were also a number of other measures that were ranked more highly by patients and their parents, including fatigue, pain, discontinuation of medication/steroids, and medication side effects. Again, the importance of asking patients about which outcomes matter to them is demonstrated.

This work by Mecoli, et al is an important step in the development and adoption of valid outcome measures for patients with IIM1. It has the potential to affect both the conduct of clinical trials and the provision of clinical care. This study also identifies areas that will require additional research, because validated assessment of domains such as fatigue or cognitive impairment is currently not available for IIM. Finally, this work emphasizes the critical importance of directly involving patients, and where appropriate their caregivers, in outcomes research to ensure that all relevant domains are considered.

Footnotes

  • See IIM perceptions, page 106

REFERENCES

  1. 1.
    1. Mecoli CA,
    2. Park JK,
    3. Alexanderson H,
    4. Regardt M,
    5. Needham M,
    6. de Groot I,
    7. et al.
    Perceptions of patients, caregivers, and healthcare providers of idiopathic inflammatory myopathies: an international OMERACT study. J Rheumatol 2019;46:106–111.
  2. 2.
    1. Regardt M,
    2. Welin Henriksson E,
    3. Alexanderson H,
    4. Lundberg IE
    . Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study. Rheumatology 2011;50:578–85.
  3. 3.
    1. Tugwell P,
    2. Boers M,
    3. Brooks P,
    4. Simon L,
    5. Strand V,
    6. Idzerda L
    . OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38.
  4. 4.
    1. Boers M,
    2. Kirwan JR,
    3. Tugwell P,
    4. Beaton D,
    5. Bingham CO III,
    6. Conaghan PG,
    7. et al;
    8. The OMERACT Handbook: OMERACT
    ; 2018.
  5. 5.
    1. Callahan LF
    . The history of patient-reported outcomes in rheumatology. Rheum Dis Clin North Am 2016;42:205–17.
  6. 6.
    1. Regardt M,
    2. Basharat P,
    3. Christopher-Stine L,
    4. Sarver C,
    5. Bjorn A,
    6. Lundberg IE,
    7. et al.
    Patients’ experience of myositis and further validation of a myositis-specific patient reported outcome measure - establishing core domains and expanding patient input on clinical assessment in myositis. Report from OMERACT 12. J Rheumatol 2015;42:2492–5.
  7. 7.
    1. Tory HO,
    2. Carrasco R,
    3. Griffin T,
    4. Huber AM,
    5. Kahn P,
    6. Robinson AB,
    7. et al.
    Comparing the importance of quality measurement themes in juvenile idiopathic inflammatory myositis between patients and families and healthcare professionals. Pediatr Rheumatol Online J 2018;16:28.

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire